They show that Tmab-coated human breast cancer cell lines could enhance expression of CD137 on the surface of human NK cells, and agonistic αCD137 could enhance explosion of type-I cytokines, such as IFNγ, from that NK cells, resulted in overdriving NK cell-mediated ADCC against targets. The gene discussed is TNFRSF9; the disease is breast carcinoma.